Back to Search
Start Over
Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib.
- Source :
- Clinical Case Reports; Jan2023, Vol. 11 Issue 1, p1-7, 7p
- Publication Year :
- 2023
-
Abstract
- Myeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations who was treated with the combination of the second‐generation TKI nilotinib and JAK1/JAK2 inhibitor ruxolitinib. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20500904
- Volume :
- 11
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Clinical Case Reports
- Publication Type :
- Academic Journal
- Accession number :
- 161548503
- Full Text :
- https://doi.org/10.1002/ccr3.6801